IDEAYA Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of IDEAYA Biosciences generated cash of -$115,224,000, which is less than the previous year. Cash used in financing activities reached the amount of $362,717,000 last year. Net change in cash is therefore $89,037,000.
Cash Flow
| 2017 | -12.22M | -8.92M | 17.49M |
|---|---|---|---|
| 2018 | -27.62M | -63.17M | 105.37M |
| 2019 | -39.31M | 2.26M | 50.61M |
| 2020 | 55.46M | -146.24M | 128.75M |
| 2021 | -55.77M | -69.66M | 145.45M |
| 2022 | -87.17M | -33.40M | 97.16M |
| 2023 | -115.22M | -158.45M | 362.71M |
IDYA Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 68.73M | 92.15M | 72.14M | 34.17M | 20.61M | 6.03M | 9.69M |
Operating activities | |||||||
Net income | -112.96M | -58.65M | -49.76M | -34.49M | -41.97M | -34.34M | -11.86M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 4.00M | 2.10M | 1.72M | 1.38M | 1.24M | 886K | 391K |
Stock-based compensation expense | 18.48M | 11.62M | 8.23M | 3.60M | 2.16M | 0 | 136K |
| Deferred income tax benefit | 18.48M | 11.62M | 8.23M | 3.60M | 2.16M | 0 | 136K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 193K | 892K | 774K | -1.87M | 0 | 0 | 0 |
Inventories | 0 | 0 | 3.78M | 2.28M | 0 | 0 | 0 |
Accounts payable | 2.63M | 1.86M | 1.16M | 225K | -195K | 322K | 254K |
Cash generated by operating activities | -115.22M | -87.17M | -55.77M | 55.46M | -39.31M | -27.62M | -12.22M |
Investing activities | |||||||
Purchases Of Investments | -595.98M | -255.80M | -314.99M | -242.31M | -88.00M | -133.30M | -13.47M |
Investments In Property Plant And Equipment | -2.36M | -3.44M | -2.64M | -493K | -1.35M | -1.70M | -1.75M |
Acquisitions Net | 0 | 33.40M | 67.02M | -18K | -8K | 0 | 0 |
Cash generated by investing activities | -158.45M | -33.40M | -69.66M | -146.24M | 2.26M | -63.17M | -8.92M |
Financing activities | |||||||
Common Stock Issued | 309.76M | 94.96M | 145.45M | 127.23M | 50.32M | 105.37M | 17.49M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 362.71M | 97.16M | 145.45M | 128.75M | 50.61M | 105.37M | 17.49M |
Net Change In Cash | 89.03M | -23.41M | 20.00M | 37.97M | 13.56M | 14.57M | -3.66M |
Cash at end of period | 157.77M | 68.73M | 92.15M | 72.14M | 34.17M | 20.61M | 6.03M |
| Data source | Data source | Data source | Data source | Data source |